Better Performance of PIVKA-II for Detecting Hepatocellular Carcinoma in Patients with Chronic Liver Disease with Normal Total Bilirubin

BACKGROUNDSerum protein induced by vitamin K absence or antagonist-II (PIVKA-II) is a promising biomarker for hepatocellular carcinoma (HCC) surveillance.AIMTo identify the contributing factors related to the abnormal elevation of PIVKA-II level and assess their potential influence on the performance of PIVKA-II in detecting HCC.METHODSThis study retrospectively enrolled in 784 chronic liver disease (CLD) patients and 267 HCC patients in Mengchao Hepatobiliary Hospital of Fujian Medical University from April 2016 to December 2019. Logistic regression and the area under the receiver operating characteristic curve (AUC) were used to evaluate the influencing factors and diagnostic performance of PIVKA-II for HCC, respectively.RESULTSElevated PIVKA-II levels were independently positively associated with alcohol-related liver disease, serum alkaline phosphatase (ALP), and total bilirubin (TBIL) for CLD patients and aspartate aminotransferase (AST) and tumor size for HCC patients (all P < 0.05). Serum PIVKA-II were significantly lower in patients with viral etiology, ALP <= 1 x upper limit of normal (ULN), TBIL <= 1 x ULN, and AST <= 1 x ULN than in those with nonviral disease and abnormal ALP, TBIL, or AST (all P < 0.05), but the differences disappeared in patients with early-stage HCC. For patients with TBIL <= 1 x ULN, the AUC of PIVKA-II was significantly higher compared to that in patients with TBIL > 1 x ULN (0.817 vs 0.669, P = 0.015), while the difference between ALP <= 1 x ULN and ALP > 1 x ULN was not statistically significant (0.783 vs 0.729, P = 0.398). These trends were then more prominently perceived in subgroups of patients with viral etiology and HBV alone.CONCLUSIONSerum PIVKA-II has better performance in detecting HCC at an early stage for CLD patients with normal serum TBIL.